

The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis

Craig S. Clements^{†‡}, Hugh H. Reid^{†‡§}, Travis Beddoe^{†‡}, Fleur E. Tynan[†], Matthew A. Perugini[¶], Terrance G. Johns[¶], Claude C. A. Bernard^{§††}, and Jamie Rossjohn^{†,††}

[†]Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3168, Australia; [§]Neuroimmunology Laboratory, Biochemistry Department, La Trobe University, Bundoora, Victoria 3083, Australia; [¶]Department of Biochemistry, Melbourne University, Parkville, Victoria 3010, Australia; and [¶]Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Level 6, Harold Stokes Building, Studley Road, Heidelberg 3084, Australia

Edited by David R. Davies, National Institutes of Health, Bethesda, MD, and approved July 21, 2003 (received for review May 25, 2003)

Myelin oligodendrocyte glycoprotein (MOG) is a key CNS-specific autoantigen for primary demyelination in multiple sclerosis. Although the disease-inducing role of MOG has been established, its precise function in the CNS remains obscure. To gain new insights into the physiological and immunopathological role of MOG, we determined the 1.8-Å crystal structure of the MOG extracellular domain (MOG_{ED}). MOG_{ED} adopts a classical Ig (Ig variable domain) fold that was observed to form an antiparallel head-to-tail dimer. A dimeric form of native MOG was observed, and MOG_{ED} was also shown to dimerize in solution, consistent with the view of MOG acting as a homophilic adhesion receptor. The MOG₃₅₋₅₅ peptide, a major encephalitogenic determinant recognized by both T cells and demyelinating autoantibodies, is partly occluded within the dimer interface. The structure of this key autoantigen suggests a relationship between the dimeric form of MOG within the myelin sheath and a breakdown of immunological tolerance to MOG that is observed in multiple sclerosis.

Multiple sclerosis (MS) is an inflammatory disease of the CNS characterized by localized myelin destruction and axonal degeneration (1). An autoimmune reaction against myelin antigens of the CNS contributes to the immunopathological mechanisms of this enigmatic disease. This concept is supported by observations in patients with MS such as elevated levels of lymphocytes reactive to myelin antigens, the presence of oligoclonal Ig in the cerebrospinal fluid, and perivascular inflammatory cell invasion of the CNS (2). Immune responses to abundant proteins of the CNS myelin sheath, proteolipid protein (PLP), and myelin basic protein (MBP) are thought to produce some of the pathological lesions in MS and its animal model, experimental autoimmune encephalomyelitis (EAE). However, there is another important autoantigen linked to the pathogenesis of both MS and EAE, the myelin oligodendrocyte glycoprotein (MOG), which is a minor component of the myelin sheath ($\approx 0.05\%$ of total myelin protein) (3). In susceptible animals, immunization with native or recombinant MOG, or MOG-derived peptides, or passive transfer of MOG-specific T cells and autoantibodies against MOG elicits a severe neurological disease that mimics many of the clinical, pathological, and immunological features of MS (2, 4, 5). A number of encephalitogenic epitopes of MOG (MOG₁₋₂₂, MOG₃₅₋₅₅, and MOG₉₂₋₁₀₆) have been identified (4, 6, 7). MOG₃₅₋₅₅, in particular, is a potent encephalitogen that, in contrast to MBP and PLP, elicits striking inflammatory and demyelinating immune responses in the CNS not only in various species but also across different strains of mice (5, 6, 8).

The ensuing MS-like disease is characterized by relapses and remissions, extensive neural inflammation and demyelination, axonal injury, and the production of antibodies to MOG (5, 7–10). Moreover, antibodies to MOG are directly associated with myelin damage in the marmoset model of EAE as well as in the CNS of patients with MS (10). The epitopes recognized by mAb 8-18C5 and other demyelinating mAbs to MOG are conforma-

tion-dependent (11), whereas antibodies against linear epitopes of MOG do not induce widespread demyelination (12).

MOG is a type I integral membrane protein possessing a single extracellular Ig variable domain (Ig-V) (3, 13, 14). The amino acid sequence of MOG is highly conserved among animal species ($>90\%$), indicative of an important biological function. MOG is specifically expressed in the CNS on the outermost lamellae of the myelin sheath as well as the cell body and processes of oligodendrocytes (3). The developmentally late expression of MOG correlates with the later stages of myelinogenesis, suggesting that MOG has a role in the completion, compaction, and/or maintenance of myelin, further suggesting that MOG has an adhesive function within the CNS (3). Consistent with MOG's possible adhesive role in the CNS, a homodimeric form of MOG has not only been observed after isolation from the CNS but has additionally been observed *in situ* (15). In addition, MOG may also have an immune-related function because it binds C1q, and thus could be a regulator of the classical complement pathway (16).

We have determined the 1.8-Å crystal structure of MOG extracellular domain (MOG_{ED}) to further our understanding of the function of this protein and to elucidate its role in the pathogenesis of demyelinating diseases of the CNS.

Methods

Protein Expression and Refolding. MOG_{ED} (residues 1–117) of the mature mouse protein, containing an amino terminal six-histidine tag, was produced in the *Escherichia coli* strain M15 (pREP4) by using the pQE9 expression vector (Qiagen, Melbourne, Australia). After expression and preparation of a cleared lysate per the manufacturer's instructions, MOG_{ED} was purified by using Ni-NTA Superflow (Qiagen) under denaturing conditions (6 M guanidine-HCl), per the manufacturer's instructions, on a BioLogic LP Chromatography System (Bio-Rad). The column was washed to remove nonspecifically bound material, and bound protein was refolded directly on the column by using linear gradients of denaturing versus nondenaturing solutions. After elution with 300 mM imidazole in sodium phosphate/Tris (pH 8.0), MOG_{ED} was dialyzed against 50 mM NaCl/5 mM Tris (pH 8.0) and concentrated to 1.3 mg/ml.

Crystallization. Crystallization trials were conducted by using the hanging-drop vapor diffusion technique at room temperature.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: DTSSP, 3,3'-dithiobis(sulfosuccinimidyl)propionate; EAE, experimental autoimmune encephalomyelitis; MOG, myelin oligodendrocyte glycoprotein; MOG_{ED}, MOG extracellular domain; MS, multiple sclerosis; P₀, myelin protein zero.

Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.rcsb.org (PDB ID code 1PY9).

[†]C.S.C., H.H.R., and T.B. contributed equally to this work.

^{††}To whom correspondence may be addressed. E-mail: jamie.rossjohn@med.monash.edu.au or c.bernard@latrobe.edu.au.

© 2003 by The National Academy of Sciences of the USA

Table 1. Data collection and refinement statistics

Data collection	
Temperature, K	100
Space group	I4 ₁
Cell dimensions, Å (<i>a</i> , <i>b</i> , <i>c</i>)	65.7, 65.7, 67.6
Resolution, Å	1.8
Total no. of observations	33,022
No. of unique observations	13,229
Multiplicity	2.5
Data completeness, %	99.0 (100.0)
Data >2 σ _{<i>i</i>} , %	79.6
<i>I</i> / σ _{<i>i</i>}	6.9 (1.8)
<i>R</i> _{merge} [*] , %	6.5 (24.6)
Refinement	
Nonhydrogen atoms	
Protein	934
Water	215
Sulfate ions	2
Resolution, Å	50–1.8
<i>R</i> _{factor} [†] , %	20.1
<i>R</i> _{free} [†] , %	23.7
rms deviations from ideality	
Bond lengths, Å	0.005
Bond angles, °	1.35
Dihedrals, °	26.3
Improper, °	0.7
Ramachandran plot	
Most favored and allowed region, %	99
<i>B</i> factors, Å ²	
Average main chain	20.3
Average side chain	24.1
Average water molecule	40.3
rms deviation in bonded <i>B</i> factors	1.8

The values in parentheses are for the highest-resolution bin (approximate interval 0.1 Å).

$$^*R_{\text{merge}} = \frac{\sum |I_{hkl} - \langle I_{hkl} \rangle|}{\sum I_{hkl}}$$

[†]*R*_{factor} = $\frac{\sum |F_o| - |F_c|}{\sum |F_o|}$ for all data except for 3% that was used for the *R*_{free} calculation.

Tetragonal-shaped crystals were grown by mixing equal volumes of MOG_{ED} with the reservoir buffer (14–18% polyethylene glycol 4000/0.1 M sodium acetate, pH 4.6). The crystals were flash frozen before data collection by using 10% glycerol. All data were collected in-house on an R-AXIS IV⁺⁺ detector with CuK α x-rays generated by a Rigaku (Tokyo) RU-H3RHB rotating anode generator and focused by using Osmic (Auburn Hills, MI) mirrors. The diffraction data were processed and analyzed by using D^{*}TREK (17) and programs from the CCP4 suite (18). The crystals diffracted to 1.8 Å and belong to space group I4₁ with unit cell dimensions *a* = *b* = 65.7 Å and *c* = 67.6 Å, consistent with one monomer per asymmetric unit. A summary of statistics is provided in Table 1.

Structure Determination and Refinement. The structure was solved by using a combination of molecular replacement (AMORE), manual rebuilding in O (19), and the ARP/WARP procedure (20). The progress of refinement was monitored by the *R*_{free} value (3% of the data). The starting model for molecular replacement was a domain from B7.2, with all differences mutated to alanine and the majority of loops removed. The highest peak in the rotation function also gave the highest peak in the translation function that packed well within the unit cell. Inspection of the electron density map suggested that the solution was correct although the phase information was poor. Given the high resolution of the data, ARP/WARP was tried; however, this procedure failed initially. Regardless, manual model rebuilding was initiated, inter-

persed with refinement within CNS (21). When a sufficient core of the model was built, ARP/WARP was reused and proceeded to successfully build and refine the model. A final round of refinement was undertaken in CNS.

The final model, comprising residues 2–117, 215 water molecules, and two sulfate ions, has an *R*_{factor} of 20.1% and an *R*_{free} of 23.7% (Table 1). One residue, His-103, although in the disallowed area of the Ramachandran plot, fits the electron density very well.

Western Blot Analysis. Myelin was prepared from the brains of adult wild-type and MOG-deficient mice (unpublished data) and human brain by using sucrose gradient centrifugation. Native MOG was purified from human brain by affinity chromatography with the MOG-specific monoclonal antibody 8-18C5 (22). Myelin proteins (2.5 μ g per lane) and purified native MOG were resolved on 12% SDS/PAGE gels. MOG was detected by Western blot analysis as described (15), using 8-18C5 and enhanced chemiluminescence detection per the manufacturer's instructions (ECL, Amersham Biosciences).

Cross-Linking. Protein for cross-linking was buffer-exchanged into PBS (50 mM phosphate/150 mM NaCl, pH 7.2) by running the protein on a Superdex 75 10/30 column (Amersham Biosciences). Increasing amounts of MOG_{ED} were incubated with 0.1 mM DTSSP [3,3'-dithiobis(sulfosuccinimidylpropionate); Pierce] for 30 min at room temperature. The reaction was quenched with 1 M Tris, and the whole reaction was analyzed by SDS/PAGE.

Blue Native PAGE. Blue native PAGE (31) was used to resolve MOG_{ED}. Briefly, MOG_{ED} was resuspended in Coomassie blue G250 (Serva) loading buffer and resolved on 4–20% native PAGE gels (Bio-Rad) at 15 mA for 2 h at 4°C. The gels were then stained in Coomassie blue R250. Chymotrypsinogen A (\approx 26 kDa) and ribonuclease A (\approx 14 kDa) were used as molecular mass standards (2 μ g per lane).

Native Gel Electrophoresis. Nondenaturing PAGE was performed by using a discontinuous buffer system. The resolving gel contained 0.37 M Tris, pH 8.8, with 3.8 mM TEMED, 3.0 mM ammonium persulfate, and specified percent acrylamide. A 4% stacking gel was used in all experiments. The gels were run for 30 min at constant voltage of 200 V with SDS-running buffer (0.1 M Tris/0.38 M glycine, pH 8.8). The gels were stained with Coomassie blue.

Biacore Analysis. The biotinylated MOG₃₅₋₅₅ and MOG₉₂₋₁₀₆ peptides were obtained from Auspep (Melbourne, Australia) and synthesized by standard fluorenylmethoxycarbonyl (Fmoc) chemistry, and purity (>95%) was determined by mass spectrometry. Biotinylated peptides were immobilized on streptavidin sensor chip and binding of MOG_{ED} analyzed by surface plasmon resonance (Biacore, Victoria, Australia). MOG_{ED} (10 μ g/ml) was passed through the flow cells at a flow rate of 10 μ l/min. After completion of each run, the sensor chip was regenerated with a pulse of 100 mM NaOH.

Results

Structure Description. The structure of MOG_{ED} has been determined to 1.8-Å resolution (Fig. 1). As predicted from sequence data, the overall structure of MOG_{ED} adopts a topology of an Ig-V domain (Fig. 1) with overall dimensions of \approx 40 \times 35 \times 30 Å. The structure adopts a compact, β -sandwich domain with one antiparallel β -sheet (strands A, B, E, and D) packing against a mixed β -sheet (strands A', G, F, C, C', and C'') with the N and C termini at opposite ends of the molecule. In addition to the β -strands, there are four ₃10 helices located at the periphery of




Fig. 1. Schematic of the MOG monomer. The secondary structure assignment is as follows: β A (4–6); β A' (12–15); β B (20–27); β C (36–42); β C' (47–52); β C'' (55–56); β D (69–72); β E (80–85); β F (94–102); and β G (105–116). The disulfide bond is shown in green. Each β -sheet is color-coded.

the molecule. The core packing residues of MOG_{ED} are similar to what is observed in other Ig-V domains, namely a canonical disulfide bond (Cys-24–Cys-98) that packs against the consensus residue (Trp-39), as well as the conserved and buried salt bridge between residues Arg-68 and Asp-92.

The three loops at the membrane-distal end of MOG_{ED} that connect the B–C, C'–C'', and F–G strands have been termed Loops 1, 2, and 3, respectively. These loops are in the homologous location of the complementarity determining regions (CDRs 1, 2, and 3, respectively) of the Ig-V domains. The three loops combine to form a polar and essentially uncharged flat face in which His-103 at the tip of Loop 3 protrudes.

MOG_{ED} possesses a significant strip of electronegative charge that runs about half the length of the molecule, terminating at a small band of electropositive charge (Arg-4, Arg-25, Lys-80) (Fig. 2 Upper). This electronegative strip is dominated by residues at the N-terminal region of the B β -strand (Asp-18, Glu-19, Glu-21) but also contains Glu-74 and Glu-116. Surface-exposed hydrophobic patches can also be indicative of regions that mediate protein–protein and/or –ligand interactions. MOG_{ED} possesses a number of solvent-accessible hydrophobic residues, including three aromatics: Tyr-10, Phe-44, and Phe-90 (Fig. 2 Lower).

Structural Comparisons. Automated structure comparisons (24) against other Ig-V domain structures revealed MOG_{ED} to be the most structurally homologous to sialoadhesin (rmsd 1.6 Å for 105 C α atoms), despite sharing only 24% amino acid sequence identity. Additionally, a number of significant matches were made with other receptors identified in cell adhesion/receptor–ligand interactions, including b7-2 (25), adenovirus receptor D1 domain (CAR) (26), myelin protein zero (P₀) (27), and junctional adhesion molecule (JAM) (28). In comparing the structure of MOG_{ED} to sialoadhesin (29) and P₀, the core secondary structural elements superimpose well, reflecting the conserved core-packing residues (Fig. 3). The major structural differences reside at the A–A' interconnecting region, Loop 1, the C–C' loop, part of Loop 2, residues 73–78, and residues within Loop 3.




Fig. 2. Surface representations of MOG. (Upper) Electrostatic potential, highlighting the electronegative strip. Residues contributing to this feature are labeled. (Lower) The solvent-exposed hydrophobic residues, Tyr-10 and Phe-44, in the same orientation to that in Upper.

The Dimer. MOG_{ED} was purified predominantly as a monomer and crystallizes as a monomer in the asymmetric unit. However, the observed contacts within the crystalline lattice was suggestive of a biologically relevant, higher-order oligomer of MOG_{ED}, namely a MOG dimer. There are three regions of crystal contacts observed within the lattice of MOG; two of these




Fig. 3. Sequence alignment of the MOG sequences (mMOG, mouse; rMOG, rat; bMOG, bovine; hMOG, human; qMOG, quokka), as well as closely related structural homologues CAR, JAM, and P₀. Secondary structure elements relating to the MOG structure are shown above the alignment. Identical residues are boxed and in red, and conservatively substituted residues are in blue. The major encephalitogenic peptides (1–22, 35–55, and 92–106) are shown underneath the MOG sequences. Shaded residues represent regions of sequence differences between the MOG species. Numbering was done according to the MOG sequence.




Fig. 4. Schematic representation of the crystallographic head-to-tail dimer of MOGED. Mapping of the encephalitogenic peptides onto the dimer: orange, residues 1–22; red, residues 35–55; cyan, residues 92–106. All map onto the face of the β -sheet that mediates dimer contacts. Protomers A and B are colored light gray and dark gray, respectively.

interactions neither exhibited an extensive interface nor displayed significant shape complementarity. In the third crystal contact region, however, MOGED was observed to lie on a crystallographic twofold, forming an antiparallel, head-to-tail dimer within the lattice. This dimer interface (Fig. 4) is extensive, burying $\approx 1,800 \text{ \AA}^2$ of surface area, excluding water molecules. Furthermore, the shape complementarity index at the dimer interface is high (0.7), representing a value that is comparable to that observed in antibody–antigen interactions. Taken together, these global features, namely an extensive interface exhibiting high shape complementarity, suggest that the crystallographic MOGED dimer may represent a biologically relevant MOG dimer.

The dimer interface runs along the long axis of the molecule, with interactions predominantly involving the extreme N terminus, the interconnecting loop between A and A' strands (residues 8–11), the C–C' loop (residues 40–46), and the F–G strand β -hairpin (residues 95–112) (Figs. 4 and 5). The interface is dominated by van der Waals interactions and hydrogen bonds. There are 10 direct hydrogen bonds per protomer: Gly-9^O to Glu'-107^{OE1}; Pro-11^N to Glu'-107^{OE1}; Ser-45^{OG} to Ser'-45^{OG}; Thr-97^{OG1} to Thr'-97^{OG1}; Glu-106^{NE2} to Glu'-112^{OE1}; Glu-107^{OE1} to Gly'-9^O; Glu-107^{OE1} to Pro'-11^N; Glu-108^{OE2} to Glu'-112^{OE1}; Glu-112^{OE1} to Gln'-106^{NE2}; Glu-112^{OE1} to Gln'-106^{OE2}. Residues from the F–G β -hairpin participate extensively at this interface, with water molecules being largely excluded from this F–G β -hairpin area of the interface (Fig. 5 Upper). The small side chain of Ala-110 interacts with its counterpart. Ala-109 and Ala-110 are flanked by long acidic side chains of Glu-112, Glu-108, and Glu-107 that cluster to form an unusual triad of residues that interact at the interface. The periphery of this interface is dominated by the polar side chains Gln-106 and Tyr-105.

Adjacent to Ala-109 is a water-filled cavity that mediates interactions with the A–A' strand loop. This loop is unusual in that it bulges away from the body of the Ig-V fold, toward the dimer interface (Fig. 5 Upper). Within this bulged loop is the prominent aromatic, Tyr-10, which is fully solvent-exposed in the monomer but in the dimeric state stacks between the aliphatic moieties of Gln'-2 and Arg'-4 from the opposing protomer.




Fig. 5. Stereoviews of the interactions at the dimer interface. (Upper) Centered around the F–G β -hairpin, shown in the same orientation as Fig. 4. Contacting residues are in ball-and-stick format, and hydrogen bonds are shown as dashed lines. Protomers A and B are colored light gray and dark gray, respectively. (Lower) Close-up of the interactions at C–C' loop. Residues are shown in ball-and-stick format, water molecule are shown as blue spheres, and hydrogen bonding is shown as a dashed line. Protomers A and B are in yellow and red, respectively.

The C–C' loop (residues 40–46) (Figs. 1 and 5 Lower) interacts with each other, in an orientation that is $\approx 70^\circ$ to that of the β -hairpin-mediated interaction. This loop contains two aromatics, Phe-44 and Tyr-40, and a *cis* proline, Pro-43, that packs against Tyr'-40 and Phe'-99. The side chain of Phe-44 is completely solvent-exposed and does not form intersubunit contacts with its side chain. The main chain of Phe-44 does, however, form van der Waals contacts with Ser'-45, a residue that hydrogen-bonds onto itself. There are a number of water-mediated hydrogen bonds centered around this loop (Fig. 5 Lower).

Native MOG has been repeatedly reported to exist as a mixture of monomeric and dimeric species (3, 15, 22). We also observed that, in Western analysis, the MOG-specific monoclonal antibody, 8-18C5, recognizes proteins with relative mass of 26–28 kDa (monomeric MOG) and 54 kDa (dimeric MOG) in CNS myelin from mouse and human brain as well as native MOG purified from human brain (Fig. 6A).

To confirm that the observed MOGED dimer was not merely due to crystal packing artifacts, several biochemical techniques were used to ascertain whether MOGED formed a dimer in solution. Firstly, we performed cross-linking studies, using an approach that has proved informative in other studies examining receptor self-association (30). In the presence of the primary amine-coupling agent DTSSP, increasing concentrations of MOGED lead to the formation of a MOGED species with the

negative strip, and an exposed aromatic residue (Phe-44 of the C-C' loop) (Fig. 2), features that may represent a potential binding site (32). Interestingly, Tyr-44 of sialoadhesin, the structural equivalent of MOG_{ED} Phe-44, interacts with the ligand, sialic acid (29). One candidate ligand for MOG is the complement component C1q (33), which was shown to bind specifically *in vitro* to MOG.

Several MOG-derived peptides are encephalitogenic, but the most promiscuous among these is MOG₃₅₋₅₅, for which immunization induces a severe demyelinating disease in several animal models (23). Also, MOG₃₅₋₅₅ has been identified as an immunodominant epitope for T cell responses in MS (34). Our finding that MOG₃₅₋₅₅ forms an integral part of the MOG_{ED} dimer (Fig. 4) interface leads us to speculate that the spatial location of this peptide and its participation in the dimeric structure are critical aspects in loss of immune tolerance to this particular sequence. Of interest, the two other regions of MOG that map to the dimer interface (Fig. 4) (MOG₁₋₂₂ and MOG₉₂₋₁₀₆) are also encephalitogenic in several animal models (4, 6), further supporting a relationship between localization of peptides within the MOG dimer interface and induction of demyelinating disease.

Peptides that lay deeply buried within MOG may not be easily released during antigen processing and therefore do not induce tolerance during development. Introduction of the peptide later in life, either experimentally or as a result of myelin damage, could cause disruption of the MOG dimer and so may then stimulate pathogenic immune responses given a suitable MHC background. This hypothesis is supported by the observation that in contrast to MOG₃₅₋₅₅, induction of disease by immunization with MOG_{ED} requires processing by antigen-presenting cells (35, 36).

Aside from T cells, MOG is also a known B cell autoantigen in both EAE and MS (10–12). Various MOG-specific autoantibodies cannot be mapped to any linear sequence in the MOG_{ED} and hence appear to recognize a conformational epitope (6). Not unexpectedly, conformation-dependent antibodies seem more efficient at inducing demyelination than those recognizing linear epitopes (12).

In Lewis rats immunized with MOG₃₅₋₅₅, antibodies to the peptide are associated with severe EAE, and fine epitope mapping of these antibodies reveals MOG₃₇₋₄₆ as an immunodominant region (7). This region is located at the dimer interface, an observation that raises two considerations. First, these MOG₃₇₋₄₆ autoantibodies could preferentially recognize the dimeric form of MOG, and this ability, which for example might mimic the natural ligand, may be related to their demyelinating activity. Second, given that the epitope is partly buried at the dimer interface, some autoantibodies may only recognize MOG after the dimer is disrupted. Further experimental evidence is required to clarify these considerations.

The MOG_{ED} structure suggests a link between the physiological function of MOG and its immunopathological features in MS. This work could eventually lead to the development of therapeutics designed to interfere with the anti-MOG T and B cell response in patients with MS.

We thank I. Mackay, T. Backstrom, and J. Villadangos for critical reading of the manuscript, and S. Bottomley for useful discussions. J.R. is supported by a Wellcome Trust Senior Research Fellowship in Biomedical Science in Australia. This work was supported partly by grants from the National Health and Medical Research Council, MS Australia, the J. B. Were and Son Trust, and Toward a Cure.

- Noseworthy, J. H., Lucchinetti, C., Rodriguez, M. & Weinshenker, B. G. (2000) *N. Engl. J. Med.* **343**, 938–952.
- Bernard, C. C., Johns, T. G., Slavin, A., Ichikawa, M., Ewing, C., Liu, J. & Bettadapura, J. (1997) *J. Mol. Med.* **75**, 77–88.
- Johns, T. G. & Bernard, C. C. (1999) *J. Neurochem.* **72**, 1–9.
- Linnington, C., Berger, T., Perry, L., Weerth, S., Hinze-Selch, D., Zhang, Y., Lu, H. C., Lassmann, H. & Wekerle, H. (1993) *Eur. J. Immunol.* **23**, 1364–1372.
- Slavin, A., Ewing, C., Liu, J., Ichikawa, M., Slavin, J. & Bernard, C. C. (1998) *Autoimmunity* **28**, 109–120.
- Amor, S., Groome, N., Linnington, C., Morris, M. M., Dornmair, K., Gardinier, M. V., Matthieu, J. M. & Baker, D. (1994) *J. Immunol.* **153**, 4349–4356.
- Ichikawa, M., Johns, T. G., Liu, J. & Bernard, C. C. (1996) *J. Immunol.* **157**, 919–926.
- Genain, C. P. & Hauser, S. L. (1996) *Methods* **10**, 420–434.
- Ichikawa, M., Johns, T. G., Adelman, M. & Bernard, C. C. (1996) *Int. Immunol.* **8**, 1667–1674.
- Genain, C. P., Cannella, B., Hauser, S. L. & Raine, C. S. (1999) *Nat. Med.* **5**, 170–175.
- Brehm, U., Piddlesden, S. J., Gardinier, M. V. & Linnington, C. (1999) *J. Neuroimmunol.* **97**, 9–15.
- von Budingen, H. C., Hauser, S. L., Fuhrmann, A., Nabavi, C. B., Lee, J. I. & Genain, C. P. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 8207–8212.
- Pham-Dinh, D., Mattei, M. G., Nussbaum, J. L., Roussel, G., Pontarotti, P., Roedel, N., Mather, I. H., Artzt, K., Lindahl, K. F. & Dautigny, A. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 7990–7994.
- Hilton, A. A., Slavin, A. J., Hilton, D. J. & Bernard, C. C. (1995) *J. Neurochem.* **65**, 309–318.
- Slavin, A. J., Johns, T. G., Orian, J. M. & Bernard, C. C. (1997) *Dev. Neurosci.* **19**, 69–78.
- Vanguri, P. & Shin, M. L. (1986) *J. Neurochem.* **46**, 1535–1541.
- Pflugrath, J. W. (1999) *Acta Crystallogr. D* **55**, 1718–1725.
- Collaborative Computational Project Number 4 (1994) *Acta Crystallogr. D* **50**, 760–763.
- Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M. (1991) *Acta Crystallogr. A* **47**, 110–119.
- Perrakis, A., Harkiolaki, M., Wilson, K. S. & Lamzin, V. S. (2001) *Acta Crystallogr. D* **57**, 1445–1450.
- Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) *Acta Crystallogr. D* **54**, 905–921.
- Linnington, C., Webb, M. & Woodhams, P. L. (1984) *J. Neuroimmunol.* **6**, 387–396.
- Iglesias, A., Bauer, J., Litzenburger, T., Schubart, A. & Linnington, C. (2001) *Glia* **36**, 220–234.
- Holm, L. & Sander, C. (1995) *Trends Biochem. Sci.* **20**, 478–480.
- Schwartz, J. C., Zhang, X., Fedorov, A. A., Nathenson, S. G. & Almo, S. C. (2001) *Nature* **410**, 604–608.
- van Raaij, M. J., Chouin, E., van der Zandt, H., Bergelson, J. M. & Cusack, S. (2000) *Struct. Folding Des.* **15**, 1147–1155.
- Shapiro, L., Doyle, J. P., Hensley, P., Colman, D. R. & Hendrickson, W. A. (1996) *Neuron* **17**, 435–449.
- Kostrewa, D., Brockhaus, M., D'Arcy, A., Dale, G. E., Nelboeck, P., Schmid, G., Mueller, F., Bazzoni, G., Dejana, E., Bartfai, T., et al. (2001) *EMBO J.* **20**, 4391–4398.
- May, A. P., Robinson, R. C., Vinson, M., Crocker, P. R. & Jones, E. Y. (1998) *Mol. Cell* **1**, 719–728.
- Yang, J., Dokurno, P., Tonks, N. K. & Barford, D. (2001) *EMBO J.* **20**, 3645–3656.
- Schagger, H. & von Jagow, G. (1991) *Anal. Biochem.* **199**, 223–231.
- Rossjohn, J., McKinstry, W. J., Woodcock, J. M., McClure, B. J., Hercus, T. R., Parker, M. W., Lopez, A. F. & Bagley, C. J. (2000) *Blood* **95**, 2491–2498.
- Johns, T. G. & Bernard, C. C. (1997) *Mol. Immunol.* **34**, 33–38.
- Kerlero de Rosbo, N., Hoffman, M., Mendel, I., Yust, I., Kaye, J., Bakimer, R., Flechter, S., Abramsky, O., Milo, R., Karni, A. & Ben-Nun, A. (1997) *Eur. J. Immunol.* **27**, 3059–3069.
- Slavin, A. J., Soos, J. M., Stuve, O., Patarroyo, J. C., Weiner, H. L., Fontana, A., Bikoff, E. K. & Zamvil, S. S. (2001) *J. Clin. Invest.* **108**, 1133–1139.
- Tompkins, S. M., Padilla, J., Dal Canto, M. C., Ting, J. P., Van Kaer, L. & Miller, S. D. (2002) *J. Immunol.* **168**, 4173–4183.